Timeline

Voting rights breakdown

Gemeldete wirtschaftlich Berechtigte · 2

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

• Jean-Paul Clozel27.389%
• Martine Clozel27.389%

Notice details

Beneficial owner

Jean-Paul Clozel

Date of transfers of equity securities: expected between Q1 and Q3 of 2025 As disclosed in the disclosure notification dated March 3, 2025, Jean-Paul Clozel has entered into into a lock-up agreement dated February 25, 2025 with, among others, Idorsia Ltd (the "Company"), Idorsia Pharmaceuticals Ltd ("IPL") and certain other bondholders (the "Lock-Up Agreement") and a backstop letter agreement dated February 25, 2025 with the Company, IPL and certain other bondholders (the "Backstop Letter", collectively the "Agreements"), and is thus a member of the lock-up group disclosed as of March 3, 2025. Thus this disclosure notification includes only the positions held by Jean-Paul Clozel, which are not locked under the Lock-Up Agreement and, hence are not covered by the lock-up group disclosure. Under the Agreements, Jean-Paul Clozel holds the rights to receive (positions which were allocated but not delivered, and some of which may change before final delivery): (i) to receive 4,386,723 registered shares as per different conditions and milestone events as defined in the Agreements between approximately Q1 2025 and up until Q3 2025 as follows: a) 600,000 registered shares as a backstop fee (allocated but not delivered); b) 700,000 registered shares as an arrangement fee (subject to change before final delivery); and c) 3,086,723 registered shares as an exchange fee (subject to change before final delivery). (ii) to be granted/issued warrants between approximately Q1 2025 and approximately end of Q3 2025 as per different conditions and milestone events as defined in the Agreements that (1) will have a maturity based on the maturity of the new money facility pursuant to the Lock-Up Agreement (i.e., 24 months from first utilisation of the new money facility), and (2) an exercise price of CHF 1.50 per warrant for the delivery of up to 4,253,387 registered shares as follows: a) up to 533,332 registered shares as a backstop fee (allocated but not delivered); b) up to 633,332 registered shares as an arrangement fee (subject to change before final delivery); and c) up to 3,086,723 registered shares as an exchange fee (subject to change before final delivery). As stated in the disclosure notification dated March 3, 2025, the previous positions regarding (1) the convertible bonds 2025 (ISIN CH0426820350; 0.75 IDORSIA CV 18-25) issued by the Company (the "CB25") and (2) the convertible bonds 2028 (ISIN CH1128004079; 2.125 IDORSIA CV 21-28) issued by the Company (the "CB28"): a) 9,466,667 voting rights with regard to CB25; and b) 5,516,804 voting rights with regard to CB28, are now covered by the separate lock-up group disclosure regarding the lock-up group, as disclosed as of March 3, 2025.